Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Colorectal Neoplasms 86Colonic Neoplasms 32Rectal Neoplasms 31Neoplasms 24Pancreatic Neoplasms 22Stomach Neoplasms 20Neoplasm Metastasis 20Esophageal Neoplasms 20Neuroblastoma 12Glioma 11Sarcoma 9Glioblastoma 9Small Cell Lung Carcinoma 8Carcinoma, Non-Small-Cell Lung 8Brain Neoplasms 8Adenocarcinoma Of Esophagus 8Rhabdomyosarcoma 7Lung Neoplasms 7Sarcoma, Ewing 6Gliosarcoma 6Esophageal Squamous Cell Carcinoma 6Medulloblastoma 5Central Nervous System Neoplasms 5Breast Neoplasms 5Parkinson Disease 4, Autosomal Dominant Lewy Body 4Intestinal Neoplasms 4Gastrointestinal Neoplasms 4Digestive System Neoplasms 4Digestive System Diseases 4Adenocarcinoma 4

Interventions

Paclitaxel 6Carboplatin 6Gemcitabine 3pembrolizumab 2Irinotecan 2Erlotinib Hydrochloride 2Capecitabine 2Bevacizumab 2sintilimab 1pertuzumab 1pemigatinib 1olaparib 1ivosidenib 1ipatasertib 1etoposide phosphate 1erythromycin propionate-N-acetylcysteinate 1entrectinib 1cobimetinib 1belinostat 1atezolizumab 1antineoplaston AS 2-1 1antineoplaston A10 1alectinib 1Vemurafenib 1Surveys and Questionnaires 1Oxaliplatin 1HhAntag691 1Everolimus 1Etoposide 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Neoplasms, Unknown Primary × Irinotecan × Clear all
NCT00066781 2017-04-04

Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary

Alliance for Clinical Trials in Oncology

Phase 2 Completed
31 enrolled 8 charts
Tumor-Agnostic

Neoplasms, Unknown Primary

NCT00193596 2013-05-03

Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site

SCRI Development Innovations, LLC

Phase 3 Completed
198 enrolled 7 charts
Tumor-Agnostic

Neoplasms, Unknown Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡